for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BIO-TECHNE Corp

TECH.OQ

Latest Trade

387.35USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

228.66

 - 

444.83

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
387.35
Open
--
Volume
--
3M AVG Volume
4.33
Today's High
--
Today's Low
--
52 Week High
444.83
52 Week Low
228.66
Shares Out (MIL)
38.89
Market Cap (MIL)
15,609.95
Forward P/E
61.13
Dividend (Yield %)
0.32

Next Event

Q4 2021 Bio-Techne Corp Earnings Release

Latest Developments

More

Bio-Techne Reports Q3 GAAP EPS $1.12

Bio-Techne To Acquire Asuragen

Bio-Techne And Luminary Therapeutics Sign License Agreement For Use Of Bio-Techne's Tcbuster™ For The Development Of Luminary's Car-T Cell Therapies

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About BIO-TECHNE Corp

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences reporting segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biotechnology community. The Protein Sciences segment also provides an array of platforms useful in various areas of protein analysis. The Diagnostics and Genomics reporting segment provides blood chemistry and blood gas quality controls, hematology instrument controls, diagnostics immunoassays and other bulk and custom reagents for the in vitro diagnostic market.

Industry

Biotechnology & Drugs

Contact Info

614 McKinley Pl NE

MINNEAPOLIS, MN

55413-2610

United States

+1.612.3798854

https://www.bio-techne.com/

Executive Leadership

Robert V. Baumgartner

Independent Chairman of the Board

Charles R. Kummeth

President, Chief Executive Officer, Director

James T. Hippel

Chief Financial Officer, Executive Vice President - Finance

David Eansor

President - Protein Sciences

Kim Kelderman

President - Diagnostics and Genomics

Key Stats

1.82 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.6K

2019

0.7K

2020

0.7K

2021(E)

0.9K
EPS (USD)

2018

4.540

2019

4.510

2020

4.550

2021(E)

6.541
Price To Earnings (TTM)
87.45
Price To Sales (TTM)
18.41
Price To Book (MRQ)
10.13
Price To Cash Flow (TTM)
58.28
Total Debt To Equity (MRQ)
13.99
LT Debt To Equity (MRQ)
13.18
Return on Investment (TTM)
9.59
Return on Equity (TTM)
9.00

Latest News

Latest News

BRIEF-Bio-Techne Continues To Expand Portfolio To Support SARS-CoV-2 And Covid-19 Research

* BIO-TECHNE CORP - CONTINUES TO EXPAND ITS PORTFOLIO TO SUPPORT SARS-COV-2 AND COVID-19 RESEARCH AND THERAPEUTIC DEVELOPMENT Source text for Eikon: Further company coverage:

BRIEF-Bio-Techne Announces Release Of GMP ProDots Proteins

* BIO-TECHNE ANNOUNCES RELEASE OF GMP PRODOTS PROTEINS TO SUPPORT CELL AND GENE THERAPY MANUFACTURING WORKFLOWS Source text for Eikon: Further company coverage:

BRIEF-Bio-Techne And Kantaro Biosciences Announce Partnership To Develop And Scale Production Of Covid-19 Serology Test

* BIO-TECHNE AND KANTARO BIOSCIENCES ANNOUNCE PARTNERSHIP TO DEVELOP AND SCALE PRODUCTION OF COVID-19 SEROLOGY TEST

BRIEF-Bio-Techne Releases Third Quarter Fiscal 2020 Results

* Q3 EARNINGS PER SHARE ESTIMATE $1.15 -- REFINITIV IBES DATA

BRIEF-Bio-Techne's Exosome Diagnostics Launches Exodx Prostate At-Home Collection Kit

* BIO-TECHNE'S EXOSOME DIAGNOSTICS LAUNCHES EXODX PROSTATE AT-HOME COLLECTION KIT Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Bio-Techne - General Services Administration Has Awarded Unlimited 10-Year Reimbursement Contract To Its Exosome Diagnostics Laboratory

* BIO-TECHNE CORP - GENERAL SERVICES ADMINISTRATION HAS AWARDED AN UNLIMITED 10-YEAR REIMBURSEMENT CONTRACT TO ITS EXOSOME DIAGNOSTICS LABORATORY Source text for Eikon: Further company coverage:

BRIEF-Roche Expands Partnership With Bio-Techne To Offer Drug Discovery Researchers New Chromogenic Detection Options For Mrna Ish Tissue Analysis

* ROCHE EXPANDS PARTNERSHIP WITH BIO-TECHNE TO OFFER DRUG DISCOVERY RESEARCHERS NEW CHROMOGENIC DETECTION OPTIONS FOR MRNA ISH TISSUE ANALYSIS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up